CN101528197B - 药物应用的干燥重建囊泡制剂 - Google Patents

药物应用的干燥重建囊泡制剂 Download PDF

Info

Publication number
CN101528197B
CN101528197B CN2007800397245A CN200780039724A CN101528197B CN 101528197 B CN101528197 B CN 101528197B CN 2007800397245 A CN2007800397245 A CN 2007800397245A CN 200780039724 A CN200780039724 A CN 200780039724A CN 101528197 B CN101528197 B CN 101528197B
Authority
CN
China
Prior art keywords
active agent
liposomes
liposome
lipid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800397245A
Other languages
English (en)
Chinese (zh)
Other versions
CN101528197A (zh
Inventor
K·黑勒布兰德
A·斯舒茨
R·斯格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionet Pharma GmbH
Original Assignee
Scil Technology GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Technology GmbH filed Critical Scil Technology GmbH
Publication of CN101528197A publication Critical patent/CN101528197A/zh
Application granted granted Critical
Publication of CN101528197B publication Critical patent/CN101528197B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2007800397245A 2006-10-06 2007-10-05 药物应用的干燥重建囊泡制剂 Expired - Fee Related CN101528197B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06021093 2006-10-06
EP06021093.7 2006-10-06
PCT/EP2007/008659 WO2008040556A1 (en) 2006-10-06 2007-10-05 Dried reconstituted vesicle formation for pharmaceutical application

Publications (2)

Publication Number Publication Date
CN101528197A CN101528197A (zh) 2009-09-09
CN101528197B true CN101528197B (zh) 2013-02-13

Family

ID=38910893

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2007800397245A Expired - Fee Related CN101528197B (zh) 2006-10-06 2007-10-05 药物应用的干燥重建囊泡制剂
CNA2007800422016A Pending CN101605534A (zh) 2006-10-06 2007-10-05 脊柱髓核植入物
CN2012104557068A Pending CN102940878A (zh) 2006-10-06 2007-10-05 脊柱髓核植入物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2007800422016A Pending CN101605534A (zh) 2006-10-06 2007-10-05 脊柱髓核植入物
CN2012104557068A Pending CN102940878A (zh) 2006-10-06 2007-10-05 脊柱髓核植入物

Country Status (17)

Country Link
US (3) US9526761B2 (enExample)
EP (2) EP2081551B1 (enExample)
JP (2) JP5404402B2 (enExample)
KR (1) KR101333279B1 (enExample)
CN (3) CN101528197B (enExample)
CA (1) CA2664637C (enExample)
CY (1) CY1113934T1 (enExample)
DK (1) DK2081551T3 (enExample)
ES (2) ES2400162T3 (enExample)
HR (1) HRP20130328T1 (enExample)
PL (1) PL2081551T3 (enExample)
PT (1) PT2081551E (enExample)
RS (1) RS52706B (enExample)
RU (1) RU2443412C2 (enExample)
SI (1) SI2081551T1 (enExample)
TW (1) TWI455731B (enExample)
WO (2) WO2008040557A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258690B2 (en) 2003-03-28 2007-08-21 Relievant Medsystems, Inc. Windowed thermal ablation probe
US6907884B2 (en) 2002-09-30 2005-06-21 Depay Acromed, Inc. Method of straddling an intraosseous nerve
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
EP1868539A2 (en) 2005-04-15 2007-12-26 Musculoskeletal Transplant Foundation Vertebral disc repair
US7959683B2 (en) 2006-07-25 2011-06-14 Musculoskeletal Transplant Foundation Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
CA2737374C (en) 2008-09-26 2017-03-28 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
WO2011103462A1 (en) 2010-02-18 2011-08-25 Osiris Therapeutics, Inc. Methods of manufacture of immunocompatible amniotic membrane products
WO2011134979A2 (en) * 2010-04-27 2011-11-03 Scil Technology Gmbh Stable mia/cd-rap formulation
US10390877B2 (en) 2011-12-30 2019-08-27 Relievant Medsystems, Inc. Systems and methods for treating back pain
US20130202682A1 (en) * 2012-01-24 2013-08-08 The Trustees Of Columbia University In The City Of New York Synthetic matrix vesicles for biomimetic mineralization
BR112015000174A2 (pt) * 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
IL238516B (en) 2012-11-05 2022-08-01 Relievant Medsystems Inc System and methods for creating curved pathways through bone and regulating the nerves within the bone
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
ES2726924T3 (es) * 2014-12-18 2019-10-10 Bracco Suisse Sa Formulación de microvesículas dirigidas rellenas de gas
AU2016256979B2 (en) 2015-05-04 2021-01-28 Genfit Method for preparing transmembrane pH-gradient vesicles
WO2017046314A2 (en) * 2015-09-18 2017-03-23 Sanofi Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein
WO2017176196A1 (en) * 2016-04-04 2017-10-12 Chalmers Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation
CN110582282A (zh) * 2017-04-25 2019-12-17 佐剂技术公司 三萜皂苷类似物
TWI806894B (zh) * 2017-08-28 2023-07-01 台灣微脂體股份有限公司 緩釋麻醉劑組成物及其製備方法
US11389405B2 (en) 2017-09-18 2022-07-19 North Carolina State University Artificial beta cells and methods of use thereof
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
DK3864163T3 (da) * 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
AU2020346827B2 (en) 2019-09-12 2026-03-12 Relievant Medsystems, Inc. Systems and methods for tissue modulation
AU2021306313B2 (en) 2020-07-10 2026-07-09 Relievant Medsystems, Inc. Vertebral denervation in conjunction with vertebral fusion
US12082876B1 (en) 2020-09-28 2024-09-10 Relievant Medsystems, Inc. Introducer drill
AU2021409967A1 (en) 2020-12-22 2023-08-03 Relievant Medsystems, Inc. Prediction of candidates for spinal neuromodulation
US12433668B1 (en) 2021-11-08 2025-10-07 Relievant Medsystems, Inc. Impedance stoppage mitigation during radiofrequency tissue ablation procedures
CN113995852B (zh) * 2021-11-08 2024-01-30 河北大学 Arg-脂质体微囊、微囊包封的鱼精蛋白-siRNA复合体及其制备方法和应用
CN221431621U (zh) * 2023-07-10 2024-07-30 常州富谦生物科技有限公司 一种多层膜结构

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897353A (en) * 1986-03-13 1990-01-30 University Of Southwestern Louisiana Cryogenic protection of phosphofructokinase using amino acids and zinc ions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (enExample) * 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
AU8329391A (en) * 1990-08-08 1992-03-02 Liposome Technology, Inc. Stable doxorubicin/liposome composition
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US6066331A (en) * 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU5702099A (en) * 1998-09-01 2000-03-21 Millennium Pharmaceuticals, Inc. A novel protein related to melanoma-inhibiting protein and uses thereof
EP1025871A1 (en) * 1999-01-28 2000-08-09 F. Hoffmann-La Roche Ag Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
US7435260B2 (en) * 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
DK1244388T3 (da) * 1999-12-06 2007-05-14 Warsaw Orthopedic Inc Indretning til behandling af mellemhvirvelskiver
EP1432403B1 (en) * 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
CA2486967A1 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
US7169405B2 (en) * 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
KR101153035B1 (ko) * 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물
WO2005113032A2 (en) * 2004-05-21 2005-12-01 Synthes (U.S.A.) Replacement of nucleus pulposus using a hydrogel
CA2567405A1 (en) * 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
CA2584583A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20110071056A1 (en) * 2009-09-24 2011-03-24 Rajesh K Saini Degradable Surfactants, Including Degradable Gemini Surfactants, and Associated Methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897353A (en) * 1986-03-13 1990-01-30 University Of Southwestern Louisiana Cryogenic protection of phosphofructokinase using amino acids and zinc ions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIRBY C ET AL."DEHYDRATION-REHYDRATION VESICLES: a SIMPLE METHOD FOR HIGH YIELD DRUG ENTRAPMENT IN LIPOSOMES".《BIOTECHNOLOGY, BUTTERWORTHS, LONDON, GB》.1984,第2卷(第11期),979-984. *
丁武孝等."珀酸胆固醇酯作为脂质体膜稳定剂的研究及其在制备柴胡皂苷-D脂质体中的应用".《药学学报》.2005,第40卷(第7期),623-627. *

Also Published As

Publication number Publication date
WO2008040556A1 (en) 2008-04-10
EP2081551A1 (en) 2009-07-29
US20160220638A1 (en) 2016-08-04
TW200829283A (en) 2008-07-16
DK2081551T3 (da) 2013-05-06
RU2443412C2 (ru) 2012-02-27
SI2081551T1 (sl) 2013-05-31
US20090285880A1 (en) 2009-11-19
US9526761B2 (en) 2016-12-27
JP2010505482A (ja) 2010-02-25
KR20090086397A (ko) 2009-08-12
JP5484059B2 (ja) 2014-05-07
JP5404402B2 (ja) 2014-01-29
PT2081551E (pt) 2013-02-18
RS52706B (sr) 2013-08-30
HRP20130328T1 (hr) 2013-05-31
JP2010505785A (ja) 2010-02-25
EP2081551B1 (en) 2013-01-23
CA2664637A1 (en) 2008-04-10
CY1113934T1 (el) 2016-07-27
TWI455731B (zh) 2014-10-11
ES2708851T3 (es) 2019-04-11
ES2400162T3 (es) 2013-04-08
KR101333279B1 (ko) 2013-11-27
EP2086507B1 (en) 2018-11-07
RU2009117170A (ru) 2010-11-20
CN101605534A (zh) 2009-12-16
EP2086507A1 (en) 2009-08-12
CN101528197A (zh) 2009-09-09
WO2008040557A1 (en) 2008-04-10
US20090297580A1 (en) 2009-12-03
PL2081551T3 (pl) 2013-06-28
CA2664637C (en) 2013-11-12
CN102940878A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
KR101333279B1 (ko) 약학적 응용을 위한 건조된 재구성 소포 형성
JP3676976B2 (ja) 多胞状リポソームへの薬剤封入量の調節
JP2792702B2 (ja) 乾燥時に改善された安定性を示すリポソームの調製方法
US9655848B2 (en) Liposomes for in-vivo delivery
US20040247660A1 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
Kedar et al. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes
JPH09505301A (ja) 活性物質の制御放出を有する小胞
JPH08511245A (ja) 薬剤搬送ビヒクルとしての固体脂肪ナノエマルジョン体
JPH04505319A (ja) 創傷、切傷および擦傷に対する治療剤のデリバリーとしてのリポソームの使用
JP2001515852A (ja) 多胞状リポソーム中のｉｇｆ−ｉの高封入量製剤および低封入量製剤
JP2019510048A (ja) 週１回又は隔週１回の投与に適したリラグルチドの粘弾性ゲル
CA2631243A1 (en) Liposomal compositions
JP2009507006A (ja) 鉄キレート剤を含む医薬組成物
JP2937135B2 (ja) Ｐｇｅ１含有凍結乾燥製剤及び製法
CN114302709A (zh) 包裹腺苷的脂质体
JP7401471B2 (ja) 凍結乾燥形態の医薬組成物
Berillo et al. Review of recent advances in the use of drug delivery systems in ophthalmology
KR20190053429A (ko) 음이온성 약물 전달용 지질 나노입자의 동결건조 조성물 및 방법
JPS61501686A (ja) リポソ−ム↓−ゲル組成物
EA048772B1 (ru) Фармацевтические композиции в лиофилизированной форме
US20130115270A1 (en) Anti-interleukin-1 (IL-1) antibody used as a targeting agent to treat arthritis and other diseases
JPWO1991007962A1 (ja) 脂肪乳剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130213

Termination date: 20201005

CF01 Termination of patent right due to non-payment of annual fee